Products
H4 Orphan Pharma is developing two drug candidates with strong commercial potential. Studies conducted on human cell models have demonstrated the efficacy of the action of these molecules.
Pathology
Nonclinical
Phase 1
Phase 2
Phase 3
Idiopathic Pulmonary Fibrosis
Long COVID
Dry eye syndrome
554-001
554-001
554-001
Dry eye syndrome
554-002